JP2023030106A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023030106A5 JP2023030106A5 JP2022205330A JP2022205330A JP2023030106A5 JP 2023030106 A5 JP2023030106 A5 JP 2023030106A5 JP 2022205330 A JP2022205330 A JP 2022205330A JP 2022205330 A JP2022205330 A JP 2022205330A JP 2023030106 A5 JP2023030106 A5 JP 2023030106A5
- Authority
- JP
- Japan
- Prior art keywords
- curcumin
- hours
- weeks
- curcuminoid
- lysophosphatidylcholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655095P | 2018-04-09 | 2018-04-09 | |
| US62/655,095 | 2018-04-09 | ||
| PCT/US2019/024495 WO2019199469A1 (en) | 2018-04-09 | 2019-03-28 | Dosing regimens for treatment of proliferative disorders |
| JP2020555189A JP7241426B2 (ja) | 2018-04-09 | 2019-03-28 | 増殖性障害の治療のための投薬レジメン |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555189A Division JP7241426B2 (ja) | 2018-04-09 | 2019-03-28 | 増殖性障害の治療のための投薬レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023030106A JP2023030106A (ja) | 2023-03-07 |
| JP2023030106A5 true JP2023030106A5 (https=) | 2023-04-10 |
Family
ID=68164516
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555189A Active JP7241426B2 (ja) | 2018-04-09 | 2019-03-28 | 増殖性障害の治療のための投薬レジメン |
| JP2022205330A Pending JP2023030106A (ja) | 2018-04-09 | 2022-12-22 | 増殖性障害の治療のための投薬レジメン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555189A Active JP7241426B2 (ja) | 2018-04-09 | 2019-03-28 | 増殖性障害の治療のための投薬レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11813356B2 (https=) |
| EP (1) | EP3773529B1 (https=) |
| JP (2) | JP7241426B2 (https=) |
| KR (2) | KR20240027843A (https=) |
| CN (1) | CN112272555A (https=) |
| AU (1) | AU2019250832B2 (https=) |
| CA (1) | CA3096591C (https=) |
| ES (1) | ES3061642T3 (https=) |
| MX (1) | MX2020010651A (https=) |
| TW (1) | TWI737974B (https=) |
| WO (1) | WO2019199469A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI737974B (zh) | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | 用於治療增生性失調的劑量方案 |
| EP4675742A1 (en) | 2023-02-28 | 2026-01-07 | Panasonic Intellectual Property Management Co., Ltd. | Non-aqueous electrolyte secondary battery |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244448B2 (en) * | 2000-06-30 | 2007-07-17 | Tekmira Pharmaceuticals Corporation | Liposomal antineoplastic drugs and uses thereof |
| US8563525B2 (en) * | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| US7968115B2 (en) * | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
| US8784881B2 (en) * | 2004-03-05 | 2014-07-22 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
| CN1973834A (zh) * | 2006-12-15 | 2007-06-06 | 中国科学院长春应用化学研究所 | 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用 |
| PT2146721E (pt) | 2007-05-15 | 2013-07-18 | Otsuka Pharma Co Ltd | Métodos de utilização de antagonistas da vasopressina com agentes quimioterapeuticos de antraciclina para reduzir a cardiotoxicidade e/ou melhorar a sobrevivência |
| CN101766619B (zh) * | 2008-12-30 | 2011-08-24 | 武汉大学 | 一种治疗恶性肿瘤的药物组合物及应用 |
| EP2501372A4 (en) * | 2009-11-19 | 2013-04-10 | Signpath Pharma Inc | INTRAVENOUS INFUSION OF CURCUMIN AND CALCIUM CHANNEL BLOCKER |
| US9170257B2 (en) | 2012-06-14 | 2015-10-27 | Signpath Pharma Inc. | Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin |
| DE112013004278T5 (de) * | 2012-08-31 | 2015-05-21 | Signpath Pharma Inc. | Curcumin-Er, ein liposomales PLGA-Nanocurcumin mit verlängerter oder verzögerter Freisetzung zur Minimierung der QT-Verlängerung für eine Krebstherapie |
| US20150147385A1 (en) * | 2013-11-22 | 2015-05-28 | Signpath Pharma, Inc. | Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders |
| JP6895252B2 (ja) * | 2013-12-18 | 2021-06-30 | サインパス ファルマ, インク.Signpath Pharma, Inc. | 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減 |
| KR101755245B1 (ko) | 2015-08-12 | 2017-07-07 | 연세대학교 원주산학협력단 | 단량체 염을 이용한 폴리이미드 복합체 제조방법 |
| CA2940470C (en) * | 2015-09-18 | 2019-08-20 | Signpath Pharma Inc. | Treatment for glioblastoma |
| TWI737974B (zh) | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | 用於治療增生性失調的劑量方案 |
-
2019
- 2019-03-27 TW TW108110582A patent/TWI737974B/zh active
- 2019-03-28 CN CN201980037784.6A patent/CN112272555A/zh active Pending
- 2019-03-28 ES ES19785177T patent/ES3061642T3/es active Active
- 2019-03-28 EP EP19785177.7A patent/EP3773529B1/en active Active
- 2019-03-28 WO PCT/US2019/024495 patent/WO2019199469A1/en not_active Ceased
- 2019-03-28 JP JP2020555189A patent/JP7241426B2/ja active Active
- 2019-03-28 MX MX2020010651A patent/MX2020010651A/es unknown
- 2019-03-28 KR KR1020247004962A patent/KR20240027843A/ko not_active Withdrawn
- 2019-03-28 US US17/045,431 patent/US11813356B2/en active Active
- 2019-03-28 CA CA3096591A patent/CA3096591C/en active Active
- 2019-03-28 AU AU2019250832A patent/AU2019250832B2/en active Active
- 2019-03-28 KR KR1020207031775A patent/KR102637598B1/ko active Active
-
2022
- 2022-12-22 JP JP2022205330A patent/JP2023030106A/ja active Pending
-
2023
- 2023-10-04 US US18/480,678 patent/US12551436B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Green et al. | Pegylated liposomal doxorubicin in ovarian cancer | |
| RU2640485C2 (ru) | Комбинированное лечение рака | |
| CN106456626B (zh) | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 | |
| US20070265213A1 (en) | Use of Docetaxel/Doxorubicin/Cyclophosphamide in Adjuvant Therapy | |
| JP2023030106A5 (https=) | ||
| Kouroussis et al. | High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study | |
| BRPI0707059A2 (pt) | método de formação de uma micela que compreende oxaliplatina, método de encapsulação de oxaliplatina em um lipossomo, micela, lipossomo, lipossomo que compreende uma quantidade eficaz de oxaliplatina, uso de um lipossomo, método de tratamento de cáncer e terapia de combinação | |
| Alexopoulos et al. | Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer | |
| AU2019266150A1 (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
| Mrozek et al. | Phase I trial of liposomal encapsulated doxorubicin (Myocet™; D-99) and weekly docetaxel in advanced breast cancer patients | |
| Numico et al. | Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| AU2016383697A1 (en) | Treatment of breast cancer using a combination of a cationic liposomal formulation of taxane, a non-liposomal formulation of taxane and a further active agent | |
| US20110159080A1 (en) | Composition comprising liposome-entrapped doxorubicin and methods of administration | |
| WO2000069467A1 (en) | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound | |
| Jones et al. | Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin | |
| WO2019023873A1 (zh) | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物 | |
| Leighl et al. | Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer | |
| WO2023284597A1 (zh) | 用于治疗癌症的组合疗法 | |
| CN111757736B (zh) | 治疗鼻咽癌的喹啉衍生物 | |
| CN115212168A (zh) | 盐酸米托蒽醌脂质体的用途 | |
| RU2519186C2 (ru) | Производное соединение холестанола для комбинированного применения | |
| WO2017178428A1 (en) | Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer | |
| AU2022308041A1 (en) | Nanoparticles for cancer treatment | |
| WO2024187968A1 (zh) | 用于治疗三阴性乳癌的药物组合物 |